* Late-Breaking data presented at EHA: all patients with pnh
treated with once-monthly dosing of ALXN1210 in phase 1/2 study
exhibit rapid and sustained reductions in ldhSays announced
today that…
The post BRIEF-Alexion Pharmaceuticals announces data from phase 1/2 study of ALXN1210 appeared first on NASDAQ.